17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls.

      Nature reviews. Drug discovery

      Animals, Anticarcinogenic Agents, therapeutic use, Drug Resistance, Neoplasm, Humans, NF-kappa B, antagonists & inhibitors, metabolism, Neoplasms, drug therapy, pathology, Signal Transduction, drug effects

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nuclear factor kappaB (NF-kappaB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-kappaB and the signalling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-kappaB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-kappaB in cancer, and the possible complications and pitfalls of such an approach, are explored.

          Related collections

          Author and article information

          Journal
          19116625
          2729321
          10.1038/nrd2781

          Comments

          Comment on this article